These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 31444673)

  • 1. Variations in external reference pricing implementation: does it matter for public policy?
    Gill J; Fontrier AM; Kyriopoulos D; Kanavos P
    Eur J Health Econ; 2019 Dec; 20(9):1375-1397. PubMed ID: 31444673
    [TBL] [Abstract][Full Text] [Related]  

  • 2. External Reference Pricing for Pharmaceuticals-A Survey and Literature Review to Describe Best Practices for Countries With Expanding Healthcare Coverage.
    Holtorf AP; Gialama F; Wijaya KE; Kaló Z
    Value Health Reg Issues; 2019 Sep; 19():122-131. PubMed ID: 31416014
    [TBL] [Abstract][Full Text] [Related]  

  • 3. International impact of external reference pricing: should national policy-makers care?
    Fontrier AM; Gill J; Kanavos P
    Eur J Health Econ; 2019 Nov; 20(8):1147-1164. PubMed ID: 31289948
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overview of external reference pricing systems in Europe.
    Rémuzat C; Urbinati D; Mzoughi O; El Hammi E; Belgaied W; Toumi M
    J Mark Access Health Policy; 2015; 3():. PubMed ID: 27123181
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of cross-reference pricing on pharmaceutical prices: manufacturers' pricing strategies and price regulation.
    Stargardt T; Schreyögg J
    Appl Health Econ Health Policy; 2006; 5(4):235-47. PubMed ID: 17249840
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pricing of in-patent pharmaceuticals in the Middle East and North Africa: Is external reference pricing implemented optimally?
    Kanavos P; Kamphuis BW; Fontrier AM; Colville Parkin G; Saleh S; Akhras KS
    Health Policy; 2020 Dec; 124(12):1297-1309. PubMed ID: 32962876
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Does external reference pricing deliver what it promises? Evidence on its impact at national level.
    Kanavos P; Fontrier AM; Gill J; Efthymiadou O
    Eur J Health Econ; 2020 Feb; 21(1):129-151. PubMed ID: 31583483
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The economics of parallel trade.
    Danzon PM
    Pharmacoeconomics; 1998 Mar; 13(3):293-304. PubMed ID: 10178655
    [TBL] [Abstract][Full Text] [Related]  

  • 9. How does external reference pricing work in developing countries: evidence from Iran.
    Babaie F; Motevalli MH; Mehralian G; Peiravian F; Yousefi N
    Front Pharmacol; 2023; 14():1034229. PubMed ID: 37408767
    [No Abstract]   [Full Text] [Related]  

  • 10. Differential pricing for pharmaceuticals: reconciling access, R&D and patents.
    Danzon PM; Towse A
    Int J Health Care Finance Econ; 2003 Sep; 3(3):183-205. PubMed ID: 14625999
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Price comparison of high-cost originator medicines in European countries.
    Vogler S; Zimmermann N; Babar ZU
    Expert Rev Pharmacoecon Outcomes Res; 2017 Apr; 17(2):221-230. PubMed ID: 27658050
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cross-national drug price comparisons with economic weights in external reference pricing in Germany.
    Mahlich J; Sindern J; Suppliet M
    Expert Rev Pharmacoecon Outcomes Res; 2019 Feb; 19(1):37-43. PubMed ID: 30273062
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential pricing of new pharmaceuticals in lower income European countries.
    Kaló Z; Annemans L; Garrison LP
    Expert Rev Pharmacoecon Outcomes Res; 2013 Dec; 13(6):735-41. PubMed ID: 24219049
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug Policy in Romania.
    Radu CP; Pana BC; Furtunescu FL
    Value Health Reg Issues; 2018 Sep; 16():28-32. PubMed ID: 29704726
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Implementation of medicines pricing policies in sub-Saharan Africa: systematic review.
    Koduah A; Baatiema L; de Chavez AC; Danso-Appiah A; Kretchy IA; Agyepong IA; King N; Ensor T; Mirzoev T
    Syst Rev; 2022 Dec; 11(1):257. PubMed ID: 36457058
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [International reference prices and cost minimization analysis for the regulation of medicine prices in Colombia].
    Vacca C; Acosta A; Rodriguez I
    Value Health; 2011; 14(5 Suppl 1):S16-9. PubMed ID: 21839891
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Parallel imports and the pricing of pharmaceutical products: evidence from the European Union.
    Ganslandt M; Maskus KE
    J Health Econ; 2004 Sep; 23(5):1035-57. PubMed ID: 15353192
    [TBL] [Abstract][Full Text] [Related]  

  • 18. If it ain't broke, don't price fix it: the OFT and the PPRS.
    Towse A
    Health Econ; 2007 Jul; 16(7):653-65. PubMed ID: 17595047
    [TBL] [Abstract][Full Text] [Related]  

  • 19. International Reference Pricing for Prescription Drugs in the United States: Administrative Limitations and Collateral Effects.
    Rand LZ; Kesselheim AS
    Value Health; 2021 Apr; 24(4):473-476. PubMed ID: 33840424
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A pricing policy towards the sourcing of cheaper drugs in Cyprus.
    Merkur S; Mossialos E
    Health Policy; 2007 May; 81(2-3):368-75. PubMed ID: 16949176
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.